Page 34 - பிரஞ்சு அமைச்சகம் ஆஃப் ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Feb 24, 2021 Drug reduced agitation-related events but increased time on vent and length of ICU stay Critically ill patients on mechanical ventilation who were at risk for alcohol withdrawal syndrome (AWS) had fewer agitation-related events with high-dose baclofen than placebo, a prophylactic treatment trial showed. However, the effect size was modest and the baclofen group had longer median length of mechanical ventilation (9 versus 8 days) and longer ICU stay (14 versus 11 days) compared with the placebo group, reported Karim Asehnoune, MD, PhD, of D, CHU deNantes in France, and co-authors in . “The deeper sedation experienced by patients randomized to receive baclofen compared with placebo may explain both the statistically significant decrease in the primary outcome of at least one agitation-related event and the significant increase in the prespecified secondary end points of duration of mechanical ventilation and of ICU stay,” Asehnoune and colleagues wrote.

Michael readeFisher paykelPaul smythKarim asehnouneEdwards lifesciencesNantes university hospitalUniversity of queenslandFrench ministry of healthRichmond agitation sedation scaleContributing writerFrench ministryமைக்கேல் ரெட்மீனவர் பேகெல்பால் ஸ்மித்எட்வர்ட்ஸ் ஆயுள் அறிவியல்ந்யாஂட்ஸ் பல்கலைக்கழகம் மருத்துவமனை